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OBJECTIVE— Debate remains as to whether short- or long-term glycemic instability confers
a risk of microvascular complications in addition to that predicted by mean glycemia alone. In
this study, we analyzed data from the Diabetes Control and Complications Trial (DCCT) to assess
the effect of A1C variability on the risk of retinopathy and nephropathy in patients with type 1
diabetes.
RESEARCH DESIGN AND METHODS— A1C was collected quarterly during the
DCCT in 1,441 individuals. The mean A1C and the SD of A1C variability after stabilization of
glycemia (from 6 months onwards) were compared with the risk of retinopathy and nephropathy
with adjustments for age, sex, disease duration, treatment group, and baseline A1C.
RESULTS— Multivariate Cox regression showed that the variability in A1C added to mean
A1C in predicting the risk of development or progression of both retinopathy (hazard ratio 2.26
for every 1% increase in A1C SD [95% CI 1.63–3.14], P  0.0001) and nephropathy (1.80
[1.37–2.42], P  0.0001), with the relationship a feature in conventionally treated patients in
particular.
CONCLUSIONS— This study has shown that variability in A1C adds to the mean value in
predicting microvascular complications in type 1 diabetes. Thus, in contrast to analyses of DCCT
data investigating the effect of short-term glucose instability on complication risk, longer-term
fluctuations in glycemia seem to contribute to the development of retinopathy and nephropathy
in type 1 diabetes.
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The effect that glycemic variabilitymay have on the risk of develop-ment of microvascular complica-
tions of diabetes remains controversial
(1). Studies such as the Diabetes Control
and Complications Trial (DCCT) in type
1 diabetes and the UK Prospective Diabe-
tes Study (UKPDS) in type 2 diabetes have
left little doubt that the risk of microvas-
cular complications rises exponentially as
mean blood glucose (assessed using A1C)
increases (2–5). However, with regard to
glycemic variability, the clinical evidence
has not been consistent. For example, in
the DCCT the rate of complications at a
given value of A1C was apparently higher
in the conventionally treated patients
than in those treated intensively (3), lead-
ing to the suggestion that this result may
be a consequence of larger glycemic ex-
cursions in the former group of patients as
they received fewer injections of insulin
per day (6). Nonetheless, further analyses
of the DCCT dataset has shown that
within-day glucose variability, using
seven-point laboratory measured glucose
profiles, had no additional influence on
the risk of micro- or macrovascular com-
plication risk beyond that predicted by
the mean glucose value alone (7–9). A
more recent reanalysis of the A1C data by
the DCCT group has shown that the orig-
inal differences between treatment groups
was probably an artifact of model as-
sumptions originally used and that no
discrepancies in microvascular risk at the
same A1C actually existed (10). Indeed, it
has subsequently been suggested that the
increased complication risk in conven-
tionally treated patients was simply be-
cause their blood glucose values were
higher compared with those of intensively
treated patients at the same A1C (11).
It is also currently unknown whether
short-term (within-day) variability may
have a different influence on complications
compared with longer-term (day-to-day or
week-to-week) glucose fluctuations. Cer-
tainly, data from the Pittsburgh Epidemiol-
ogy Study showed that A1C variability
seemed to be an additional risk factor for the
development of macrovascular complica-
tions (12).
It is fundamental to managing diabe-
tes for a clinician to know whether a pa-
tient with glucose instability has a higher
risk of microvascular complications than
one without, especially because many of
the recent pharmacological advances
have focused on reducing glucose vari-
ability (as well as mean glucose) largely by
targeting postprandial hyperglycemia.
Therefore, in this current study we have
analyzed the publicly available DCCT
dataset to investigate the potential for
A1C variability to have an influence on
microvascular complications.
RESEARCH DESIGN AND
METHODS— We used the publicly
accessible datasets collected by the
DCCT, which were stored in SAS format
(http://www.gcrc.umn.edu). The DCCT
was a 9-year follow-up study of 1,441
participants with type 1 diabetes compar-
ing the effect of intensive versus conven-
tional blood glucose management on the
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development of the microvascular com-
plications of diabetes. At randomization,
patients were stratified into one of two
cohorts. The primary prevention cohort
(n 726) had no evidence of retinopathy
by fundus photography and a urinary al-
bumin excretion rate (AER)40 mg/24 h
(28 g/min). The secondary prevention
cohort (n  715) had only minimal reti-
nopathy, and an AER200 mg/24 h (140
g/min). The study participants were
randomly assigned into intensive (n 
711) and conventional (n  730) treat-
ment groups.
Definition of events
Severity of retinopathy was determined
by the 25-point Early Diabetic Retinopa-
thy Treatment Study (EDRTS) interim
score (2). The development and progres-
sion of sustained retinopathy was defined
as a change from baseline of 3 units on
the EDRTS score on any two successive
annual evaluations. During the 9 years of
follow-up, 242 individuals developed
sustained retinopathy, 67 of whom were
in the intensive treatment group. Nephro-
pathy was defined as an increase in AER
40 mg/24 h (28 g/min) on any annual
evaluation providing that the baseline
AER was 40 mg/dl (28 g/min). The
mean age was 27 years (range 13–39
years). Just over half (n  761, 52.8%)
were men. Average BMI was 23.4 kg/m2;
2% had a BMI 30 kg/m2. Nearly all
participants were Caucasian. The median
disease duration was 4 years. Approxi-
mately one-fifth declared themselves as
current smokers.
A1C measurement and statistical
methods
A1C was measured quarterly in both
treatment groups. In this analysis, we
only used data from 6 months into the
trial because the subjects in the inten-
sively treated group were undergoing a
period of rapidly changing glycemic con-
trol before reaching an A1C nadir at 6
months. The relationship between A1C
and the development of diabetes compli-
cations was assessed by Cox regression
from which hazard ratios (HRs) and 95%
CIs were calculated. The Cox regression
model is semiparametric in the sense that
no assumption concerning event-free sur-
vival times is necessary; it is based on the
assumption that the effect of a risk factor,
expressed as an HR, is constant over time.
The assumption of proportionality of the
Cox model covariates was tested by plot-
ting Schoenfeld residuals. All Cox regres-
sion models were adjusted for the
following baseline covariates: age (years),
sex, disease duration (years), randomiza-
tion treatment (conventional versus in-
tensive), prevention cohort (primary
versus secondary), and A1C at the study
eligibility stage.
Three models were constructed. The
first looked solely at the influence of the
updated mean A1C, from 6 months on-
wards, on the risk of subsequent micro-
vascular complications, whereas the
second model also included the variabil-
ity in A1C throughout the period ex-
pressed as SDs of A1C over all visits. As
the number of visits an individual patient
had could also influence this SD (such
that few visits would make the SD appar-
ently greater than many visits), the SD
value was also divided by[n/(n 1)] to
adjust for this possibility. The third model
expressed A1C variability as an updated
time-dependent SD (3).
Patients in the conventionally treated
group who became pregnant were un-
blinded to their A1C values and treated
with a goal of near-normal glycemia, be-
fore returning to the conventional treat-
ment protocol after delivery (13). To
ensure that our results were not influ-
enced by these 86 individuals, a separate
analysis that excluded these patients was
performed.
There has been considerable interest
in calculating coefficients of determina-
tion (r2) in models other than those for
least-squares regression. Many research-
ers have looked at developing an r2 equiv-
alent for the Cox proportional hazards
model. However, the difficulty lies in how
to take censoring into account. Because
there is no consensus on how best to mea-
sure r2 for the Cox model (14), we have
not pursued it here.
The GLIM4 and SPSS statistical com-
puter packages were used to analyze the
data. An arbitrary level of 5% statistical
significance (two-tailed) was assumed.
RESULTS— A1C variabi l i ty was
greater in the conventionally treated pa-
tients than in those treated intensively
(A1C SD 0.86 vs. 0.59). Variability was
also closely related to the mean A1C of all
patients (r 0.55), being especially so in
intensively treated patients compared
with conventionally treated patients (r 
0.71 vs. r  0.32).
Table 1 shows the relationship be-
tween the updated mean A1C and both
retinopathy and nephropathy risk in the
intensively treated group, conventionally
treated group, and both groups combined
(model 1). Models 2 and 3 show the effect
of including A1C variability (either as the
SD over the entire study duration or as an
updated SD) within the same model. In
each case in which mean A1C was initially
predictive of complications, A1C SD ei-
ther added to (or explained) the risk indi-
cated by the mean value of A1C alone.
Expressing SD after dividing by[n/(n
1)] made no difference as to the effect of
A1C variability on complication risk. In
addition, limiting the analysis to only
those conventionally treated patients who
had not become pregnant during the
DCCT did not alter the findings. For ex-
ample, in model 2, the HR for SD among
nonpregnant conventionally treated pa-
tients was 2.2 (95% CI 1.4–3.4).
Figure 1A shows the relative risk of
retinopathy progression using both treat-
ment groups combined in model 2 (Table
1) when applied to DCCT patients in the
range of 0–97.5th centile of mean A1C
after adjustment for A1C SD, using the
2.5th centile as a reference. Figure 1B
shows the same patients over the same
range of A1C SD after adjustment for
mean A1C.
CONCLUSIONS— This analysis of
the DCCT data has shown that in patients
with type 1 diabetes, increasing variability
in A1C adds to the risk of microvascular
complications over and above that pre-
dicted by the mean A1C value alone. This
finding was present in the DCCT cohort
overall and was also a feature of both
treatment groups individually when the
mean A1C alone was initially predictive.
The effect was most pronounced among
those patients who were in the conven-
tionally treated group, presumably be-
cause the event rate, the range of
variability, and the spread of variability at
any given mean A1C was much larger
than those for patients in the intensively
treated patients.
The magnitude of the effect of A1C
variability is marked, such that a 1% ab-
solute increase in A1C SD results in at
least a doubling in retinopathy and an
80% increase in nephropathy risk using
either of our models. As shown in Fig. 1B,
put into the context of individuals partic-
ipating in the DCCT, it means that a
patient in the 97.5th centile of A1C vari-
ability (SD 1.87%) has more than three
times the retinopathy risk and more than
twice the nephropathy risk of a patient in
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the 2.5th centile (SD 0.25%) for a given
A1C. The findings are in contrast to those
of a previous analysis of the DCCT data,
which suggested that A1C variability had
little effect on complication risk (3), but
probably included all patient visits, in-
cluding those before A1C stabilized at 6
months in intensively treated patients.
There are several possible reasons
for the current findings. One is that me-
dium- to long-term fluctuation in blood
glucose truly is an additional risk for the
development of microvascular complica-
tions. This fluctuation is in contrast to
within-day glucose variability, which
showed little influence on retinopathy or
nephropathy risk in the same patients in
the DCCT (7,8). The latter finding was
surprising because numerous studies
have shown that short-term glycemic ex-
cursions lead to an overproduction of re-
active oxygen species in cell cultures (15)
as well as in patients with type 2 diabetes
(16) (though not confirmed in type 1
[17]). There are also data on the effect of
longer-term changes in glycemia on free
radical production (18) as well as both
clinical and laboratory evidence that pe-
riods of sustained hyperglycemia are “re-
membered” and so place patients at
higher subsequent long-term risk of com-
plications (19,20). In this regard, the det-
rimental effect of A1C variability may be
mediated through the same mechanism
underlying that of the “metabolic mem-
ory” phenomenon (20,21).
An alternative possible explanation
for our data relates to the fact that the risk
of microvascular complications seems to
rise exponentially, rather than linearly, as
A1C rises (2,3). Thus, although patients
who have more variable A1C values will
be spending the same time above and be-
low their mean value as another with
comparatively stable A1C, their average
risk will be higher because their periods of
sustained glycemia far above their mean
will be placing them at an especially
high complication risk, which will more
than cancel out any reduction in risk
resulting from them also having equal
periods far below their mean. If true, it
would be expected that this effect
would be exaggerated as the individu-
al’s mean A1C was higher, which may
be one reason why the influence of A1C
variability seems greater in convention-
ally treated patients.
Another possible reason linking A1C
fluctuations with complication risk is the
consistent observation that improving
glycemic control can lead to a short-term
worsening in retinopathy (22,23) before
subsequently resulting in a net long-term
improvement (23): the “normoglycemic
reentry phenomenon.” Indeed, the poten-
tial for early retinopathy worsening was
one of the main concerns of improving
glucose control when the DCCT was con-
ceived. The mechanism for this paradox-
ical deterioration is not fully known but is
thought to involve changes in ocular
blood flow and increased IGF-1 concen-
trations (24) consequent on improved
glycemic control. Whatever the cause, the
cyclical improvements in glycemic con-
trol found in patients with more variable
A1C could result in a cyclical worsening
of retinopathy, which is in addition to that
predicted by the mean A1C value alone.
This excess risk, of course, could also be
compounded by the intervening periods
of worsening control. In opposition to
this hypothesis is the fact that the early
worsening of nephropathy after glycemic
improvement is not well recognized (with
the possible exception of patients in the
DCCT who became pregnant) (13), al-
though this may be more a reflection of
retinal changes becoming apparent before
those of urinary albumin.
These explanations may partially re-
concile why short-term (within-day) glu-
cose variability in the same patients has
been found to have little effect on micro-
vascular risk (7,8), whereas longer-term
instability in the form of A1C has been
found here to be much more predictive.
Alternatively, it is possible that A1C is
Table 1—Influence of updated mean A1C alone (model 1), inclusive of mean A1C SD (model 2), or updated mean A1C (model 3) on
complication risk
Intensive group HR
(95% CI) P value
Conventional group HR
(95% CI) P value
Combined HR
(95% CI) P value
Model 1
Retinopathy
Mean A1C 1.20 (1.04–1.39) 0.016 1.24 (1.12–1.36) 0.0001 1.22 (1.12–1.32) 0.0001
Nephropathy
Mean A1C 1.06 (0.96–1.17) 0.24 1.21 (1.10–1.33) 0.0001 1.13 (1.05–1.22) 0.001
Model 2
Retinopathy
Mean A1C 1.15 (0.95–1.40) 0.16 1.18 (1.07–1.29) 0.001 1.17 (1.08–1.28) 0.0001
A1C SD 2.53 (1.36–4.68) 0.003 2.11 (1.42–3.20) 0.0001 2.26 (1.63–3.14) 0.0001
Nephropathy
Mean A1C 1.052 (0.89–1.23) 0.54 1.15 (1.04–1.27) 0.005 1.11 (1.02–1.21) 0.009
A1C SD 1.51 (0.88–2.60) 0.14 2.30 (1.57–3.37) 0.0001 1.80 (1.37–2.42) 0.0001
Model 3
Retinopathy
Mean A1C 1.09 (0.97–1.23) 0.17 1.18 (1.07–1.31) 0.001 1.14 (1.05–1.24) 0.002
Updated A1C SD 3.22 (1.95–5.32) 0.0001 1.70 (1.14–2.52) 0.009 2.11 (1.54–2.89) 0.0001
Nephropathy
Mean A1C 1.03 (0.94–1.13) 0.52 1.15 (1.04–1.27) 0.004 1.08 (1.01–1.16) 0.027
Updated A1C SD 1.91 (1.21–3.10) 0.005 1.94 (1.34–2.89) 0.0001 1.86 (1.41–2.47) 0.0001
Models were adjusted for age, sex, duration, intervention group (when groups were combined), and A1C at eligibility: A1C time dependent and blood glucose time
dependent. Models used were from 6 months onward.
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more sensitive for detecting the effect of
glucose changes than daily glucose pro-
files, although the same DCCT data have
shown the mean glucose, rather than glu-
cose variability, has the major influence
on the A1C value (25).
There do not seem to be many lim-
itations in this study related to the size
and completeness of the dataset, which
is a reflection of the rigorous protocol of
the DCCT and of the dedication of the
patients involved. In sum total, the
1,441 individuals had 31,260 A1C mea-
surements performed from 6 months
into the study on which to base our con-
clusions. It must also not be forgotten
that the study benefited by being per-
formed before other potential confound-
ing factors such as antihypertensive and
lipid-lowering agents came in to common
use. Nevertheless, in interpreting these
data, it should also be remembered that
A1C in the DCCT as a whole explained no
more than 23% of the risk of retinopathy
progression for the entire cohort, with the
risk reduction associated with intensive
treatment rather than conventional treat-
ment A1C values being just a fraction of
this percentage (3).
In summary, this study has shown
that longer-term fluctuations in glycemia
seem to independently relate to the devel-
opment of retinopathy and nephropathy
in type 1 diabetes. Thus, sole measure-
ment of mean glucose or mean A1C may
not be the best predictor of complication
risk.
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